CGRP is a potent vasodilator, which means it can widen blood vessels. During a migraine attack, CGRP is released from sensory nerves, leading to inflammation and vasodilation in the meninges (the protective layers covering the brain and spinal cord). This process contributes to the intense headache and other symptoms associated with migraines. Epidemiological data reveal that migraine is a prevalent condition affecting approximately 12% of the population, with a higher incidence in women compared to men.
